This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 Nov 2021

PCI Pharma Services to build Clinical Supply Centre of Excellence in New England

The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast

To meet the growing clinical supply market demands in New England, PCI Pharma Services has announced it is constructing a new Clinical Centre of Excellence in Bridgewater, Massachusetts.

This investment makes the company the first global CDMO with integrated end-to-end capabilities to build such a centre, which will provide clinical storage, distribution and packaging with a strong focus on cold chain capabilities.

The company says the new 50,000-sq. ft centre will allow it to be closer to clients in the tri-state area and engage with more than 1000 Boston/Cambridge, the nation’s top biopharma cluster.

Brian Keesee, Vice President and General Manager, Global Operations and Supply of Clinical Services, PCI Pharma Services said the centre will also offer biopharmaceutical clients more convenience and efficiencies, as well as combining a "local feel and global capabilities".

“This expansion is part of our larger strategy to serve biopharmaceutical clients by providing a facility that can service their needs within a relatively short driving distance, while adding to our global footprint," added Keesee.

This news comes less than a month after PCI Pharma announced it is acquiring Lyophilization Services New England, a premier CDMO headquartered in Bedford, New Hampshire.

During the last 18 months, PCI has invested significantly in its global clinical sites including San Diego, Rockford, Melbourne and Berlin as part of its global clinical expansion in all services, including investing in new facilities, refrigerators and freezers, increasing capacity, and adding new storage conditions in service to both large and small molecule compounds.

Mentioned Companies
PCI Pharma Services
View company profile

Related News